Geistlich Sons
Geistlich Pharma AG is a 175-year-old Swiss family-owned regenerative biomaterials company that develops and sells bone substitutes, collagen membranes, and soft tissue matrices to dental, orthopedic, and wound care professionals across more than 110 regions globally.
- Company typePrivate
- Founded1851
- HeadquartersNew Jersey, Trinidad & Tobago
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
What Geistlich Sons does
Geistlich Pharma AG is a Swiss family-owned medical device and biomaterials company founded in 1851, headquartered in Wolhusen, Switzerland. Originally Switzerland's first glue factory processing animal bones and hides, the company pivoted into regenerative medicine in the 1980s when third-generation chemist Dr. Peter Geistlich collaborated with researchers to develop Geistlich Bio-Oss, a natural bone substitute now considered the global gold standard in regenerative dentistry. The company's core technology centers on processing bovine bone and porcine collagen into regenerative biomaterials, including bone substitutes (Bio-Oss, Orthoss), collagen membranes (Bio-Gide, Chondro-Gide), and 3D collagen matrices (Mucograft, Fibro-Gide, Derma-Gide). Geistlich's proprietary 5-week (890-hour) manufacturing process for Bio-Oss preserves the natural bone microstructure, and its Chondro-Gide bilayer collagen I/III membrane underpins the proprietary AMIC cartilage repair technique.
The company sells primarily to healthcare professionals — dental surgeons, periodontists, implantologists, orthopedic surgeons, sports medicine specialists, and wound care clinicians — across over 110 regions globally, reaching customers through 12 wholly-owned subsidiaries (UK, Germany, Italy, France, China, Brazil, South Korea, North America, Australia, New Zealand, India, Japan), direct field sales, e-commerce shops in major markets, and a global distributor network. Geistlich generates revenue primarily through one-time product sales of medical devices and biomaterials, with over 2800 peer-reviewed scientific publications supporting its products and a Geistlich product being used clinically every 14 seconds worldwide. The portfolio extends across dental, orthopedic, wound care, and infectiology applications, and is reinforced by three proprietary foundations (Osteology Foundation founded 2003, Osteo Science Foundation founded 2013, ON Foundation founded 2018) that channel research funding and connect Geistlich to global clinical leaders.
Geistlich operates with 800+ employees globally as of 2026 (its 175th anniversary year), is ISO/IEC 27001:2022 certified, and remains family-controlled under Chairman Dr. Andreas Geistlich. Recent strategic activity includes a 2019 Wolhusen facility expansion, ongoing geographic buildout through new subsidiaries (India, Brazil), and a February 2026 FDA 510(k) clearance for DermaForm obtained through a partnership with StimLabs, marking formal entry into the US advanced wound care market.
Geistlich Sons firmographics
Firmographics- Name
- Geistlich Sons
- Legal name
- Geistlich Sons Limited
- Website
- https://geistlich.com
- Company type
- Private
- Founded year
- 1851
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- Geistlich Pharma AG is a 175-year-old Swiss family-owned regenerative biomaterials company that develops and sells bone substitutes, collagen membranes, and soft tissue matrices to dental, orthopedic, and wound care professionals across more than 110 regions globally.
- Ownership category
- akta.pro rank
Geistlich Sons industry classification
Industry- Product category
- Regenerative Medical Biomaterials
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
- akta.pro secondary industries
- Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG)
Keywords
Where Geistlich Sons is headquartered
LocationHeadquarters
- HQ city
- New Jersey
- HQ country
- Trinidad & Tobago
- HQ region
- Latin America
Offices4 records
Markets served
Geistlich Sons business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Medical Device and Biomaterial Sales: Geistlich generates revenue through the sale of regenerative biomaterials and medical devices to dental professionals, orthopedic surgeons, and wound care clinicians. Products are sold directly through subsidiary companies and via distributor networks. Revenue is primarily one-time product purchase (device/biomaterial consumables), with some recurring educational services.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Geistlich Sons product offering
Product offeringCore offering
Geistlich manufactures and sells regenerative biomaterials — bone substitutes (Geistlich Bio-Oss), collagen membranes (Bio-Gide, Chondro-Gide), soft tissue matrices (Mucograft, Fibro-Gide), wound care collagen scaffolds (Derma-Gide, DermaForm), and titanium scaffolds (Yxoss CBR) — used by dental surgeons, orthopedic surgeons, and wound care clinicians for bone, cartilage, and soft tissue regeneration. The company also markets infection control products (TauroSept) and offers surgical instruments. Its biomaterials are supported by over 2,800 scientific publications and are sold across more than 110 regions through 12 subsidiaries and a distributor network.
Product overview
Geistlich is a Swiss family-owned company and global leader in regenerative medicine, offering a comprehensive portfolio of biomaterial products across dental, orthopedic, and wound care applications. The dental portfolio centers on Geistlich Bio-Oss (natural bone substitute) and Geistlich Bio-Gide (collagen membrane), complemented by soft tissue matrices (Mucograft, Mucograft Seal, Fibro-Gide), bone instruments (Micross, SafeScraper), and the Yxoss CBR titanium scaffold. The orthopedic portfolio features Orthoss bone substitutes, Chondro-Gide bilayer collagen membrane for cartilage regeneration, and the AMIC (Autologous Matrix-Induced Chondrogenesis) treatment technique. Advanced wound care includes Geistlich Derma-Gide and the newly FDA-cleared DermaForm collagen scaffold. Geistlich also offers infectiology products (Geistlich TauroSept) and partner products (OrthoPure XT, Lipogems). With over 2800 scientific publications supporting their products, Geistlich's offerings are grounded in evidence-based regenerative medicine.
Differentiator
Problem solved
Functional benefit
Products and services
- Geistlich Bio-Oss Natural bone substitute material that closely resembles the microstructure of human bone. Produced through a patented 5-week (890-hour) manufacturing process that preserves the natural bone structure. Used by dental professionals for bone augmentation, ridge preservation, sinus floor elevation and periodontal regeneration.
- Geistlich Bio-Oss Pen Easy-to-use applicator delivery format of Geistlich Bio-Oss bone substitute for guided bone regeneration procedures in dental surgery.
- Geistlich Bio-Oss Collagen Bone substitute combining 90% Geistlich Bio-Oss granules with 10% porcine collagen to improve handling and integration in guided bone regeneration procedures.
- Geistlich Combi-Kit Combined bone substitute and collagen membrane kit packaged together for guided bone regeneration procedures in dental surgery.
- Geistlich Bio-Gide (and variants: Compressed, Perio, Shape, Forte) Bilayer collagen I/III membrane that is the market-leading dental collagen membrane. The smooth surface prevents cell diffusion while the porous side supports tissue integration. Sold in multiple variants (Compressed, Perio, Shape, Forte) tailored to periodontal applications and specific surgical needs.
- Mucograft and Mucograft Seal 3D collagen matrices designed specifically for soft tissue regeneration in the oral cavity. Mucograft Seal is a ready-to-use circular version intended for socket sealing in ridge preservation procedures, eliminating the need to harvest palatal tissue.
- Fibro-Gide Porous, resorbable, volumetrically stable porcine collagen matrix specifically designed for soft tissue regeneration in the oral cavity. Designed to avoid the need for palatal tissue harvesting.
- Yxoss CBR 3D titanium scaffold for bone regeneration in dental applications, providing structural support for large bone defects. Used by dental surgeons in customized bone augmentation procedures.
- Geistlich Select REGENFAST Hyaluronic acid-based product supporting dental tissue regeneration applications, sold to dental professionals as an adjunct regenerative product.
- Pocket-X Gel Gel formulation for periodontal pocket treatment and soft tissue regeneration in dental applications.
- Allodyn Allograft Allograft bone substitute product for dental bone regeneration procedures, complementing Geistlich's xenograft portfolio.
- Micross Bone Harvester Bone harvesting instrument for collecting autogenous bone particles during dental surgery.
- SafeScraper TWIST and SafeScraper Twist Curve Volumizer Bone scraper instruments for harvesting autogenous bone during dental surgical procedures. The Twist Curve Volumizer is a curved variant for volumetric bone harvesting in specific surgical approaches.
- Geistlich Tack System Membrane fixation system for securing collagen membranes during dental regenerative procedures.
- Orthoss and Orthoss Collagen Bone substitute material for orthopedic applications that closely resembles the inorganic component of human bone tissue. Orthoss Collagen combines the bone substitute with collagen for orthopedic regeneration procedures.
- Chondro-Gide Bilayer collagen I/III membrane developed specifically for cartilage regeneration, serving as the foundation for the AMIC (Autologous Matrix-Induced Chondrogenesis) technique. Used by orthopedic surgeons for cartilage repair in knee, talus, hip and MTP joints.
- AMIC Chondro-Gide Technique Autologous Matrix-Induced Chondrogenesis (AMIC) — a minimally invasive one-step procedure combining bone marrow stimulation (BMS) with Chondro-Gide bilayer collagen membrane. The membrane creates a biological chamber that protects cells and supports cartilage tissue regeneration. Performed via mini-open or arthroscopic technique across knee, talus, hip and MTP joints.
- AMMR (Arthroscopic Matrix-based Meniscus Repair) Arthroscopic Matrix-based Meniscus Repair technique using Chondro-Gide membrane. Damaged meniscus tissue is enveloped in the collagen matrix forming a biological chamber; bone marrow blood aspirate is injected to support healing.
- AMIC Arthroscopic Instruments Specialized arthroscopic instruments for minimally invasive AMIC cartilage repair procedures in orthopedic surgery.
- Geistlich TauroSept Drug and medical device for infection control used by healthcare professionals across various clinical applications. Distributed through pharmacy and medical supply channels.
- Geistlich Derma-Gide Collagen scaffold wound care device for advanced wound care — supports wound healing for chronic and acute wounds. FDA 510(k) cleared via collaboration with StimLabs. Distributed in the U.S. by StimLabs.
- DermaForm Collagen scaffold particulate wound care device designed to protect and manage chronic and acute wounds. Obtained FDA 510(k) clearance in February 2026 through collaboration with StimLabs.
Quantifiable outcome
- A Geistlich product is used every 14 seconds worldwide
- +3 more outcomes
Companies that use Geistlich Sons
Customer profileSegments5 records
Ideal customer profiles3 records
Geistlich Sons technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature9 records
Geistlich Sons partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- StimLabscoreStimLabs, a regenerative medicine company based in Roswell, Georgia, collaborated with Geistlich to obtain FDA 510(k) clearance for DermaForm, Geistlich's collagen scaffold particulate wound care device. The partnership leverages Geistlich's biomaterial expertise and StimLabs' regulatory and commercial capabilities. The clearance was announced February 2026.
Scale indicators7 records
Recent moves10 records
Expansion highlights6 records
Geistlich Sons competitors and assessment
Company assessmentDirect peers
- Organogenesis: Commercial-stage regenerative medicine company focused on advanced wound care (Apligraf, Dermagraft) and surgical biologics. Directly comparable to Geistlich Derma-Gide and the newly FDA-cleared DermaForm in the advanced wound healing space.
- BioHorizons (Henry Schein): Dental implant and regenerative products company (now part of Henry Schein) offering bone grafting materials and membranes that directly substitute for Geistlich's Bio-Oss and Bio-Gide in dental implantology workflows.
- MiMedx Group: Regenerative medicine company specializing in placental tissue allografts for wound care and surgical recovery. Comparable to Geistlich's collagen-based wound care and dental regenerative approach via similar biomaterial-driven healing mechanisms.
- LifeNet Health: Non-profit allograft provider offering demineralized bone matrix and soft tissue grafts for dental, orthopedic, and wound care applications. Directly comparable to Geistlich's bone substitute (Orthoss, Bio-Oss) and soft tissue regeneration (Mucograft, Fibro-Gide) portfolio from an allograft-vs-xenograft angle.
- Integra LifeSciences: Specialty regenerative medicine company with deep portfolios in collagen-based wound care (Integra Dermal Regeneration Template) and orthopedic/ENT biomaterials. Directly comparable to Geistlich Derma-Gide/DermaForm (wound care) and Chondro-Gide/Orthoss (orthopedic regeneration).
- RTI Surgical: Specialty surgical implant company with biologic and metal-based solutions for spine, sports medicine, and dental procedures. Overlaps with Geistlich's orthopedic bone (Orthoss) and dental regenerative portfolio, particularly in sports medicine and cartilage indications.
Broad incumbents
- Medtronic: Diversified global medtech leader with a significant orthopedic biologics franchise (INFUSE bone graft, Grafton DBM) that competes with Geistlich's Orthoss and Bio-Oss in spine and orthopedic surgery, as well as broader regenerative medicine initiatives.
- Zimmer Biomet: Global orthopedic and dental (via ZimVie spinoff) medtech major with significant bone graft substitute and regenerative product lines. Directly comparable to Geistlich's Orthoss and Bio-Oss in orthopedic applications and adjacent to dental regenerative workflows.
- Dentsply Sirona: Large dental equipment and consumables company with regenerative and implant-adjacent product lines. Overlaps with Geistlich in dental bone substitutes and membranes, serving the same clinician base (implantologists, periodontists) with broader portfolio depth.
- Institut Straumann (Straumann Group): Global leader in dental implants and a major supplier of regenerative dental biomaterials (membranes, bone substitutes). Directly comparable to Geistlich's dental regeneration portfolio and frequently paired with Bio-Oss/Bio-Gide in clinical workflows; larger scale and broader implant offering.
Market position
Strengths1 record
Weaknesses1 record
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Geistlich Sons social profiles
Digital presenceGeistlich Sons compliance and trust
Trust signalCompliance1 record
Geistlich Sons financial estimates
Financial estimateRevenue estimate
Valuation estimate
Geistlich Sons leadership team
Management profileNumber of profiles
Profiles10 records
Geistlich Sons subsidiaries and ownership
Company hierarchySubsidiaries11 records
Geistlich Sons funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Geistlich Sons M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Geistlich Sons
What does Geistlich Sons do?
Geistlich manufactures and sells regenerative biomaterials — bone substitutes (Geistlich Bio-Oss), collagen membranes (Bio-Gide, Chondro-Gide), soft tissue matrices (Mucograft, Fibro-Gide), wound care collagen scaffolds (Derma-Gide, DermaForm), and titanium scaffolds (Yxoss CBR) — used by dental surgeons, orthopedic surgeons, and wound care clinicians for bone, cartilage, and soft tissue regeneration. The company also markets infection control products (TauroSept) and offers surgical instruments. Its biomaterials are supported by over 2,800 scientific publications and are sold across more than 110 regions through 12 subsidiaries and a distributor network.
Is Geistlich Sons a public or private company?
Geistlich Sons is a private company. It is classified as family owned and is currently operating.
When was Geistlich Sons founded?
Geistlich Sons was founded in 1851. It employs 251 to 500 people.
Where is Geistlich Sons based?
Geistlich Sons is headquartered in New Jersey, Trinidad & Tobago, in the Latin America region.
How does Geistlich Sons make money?
One revenue line is on record: medical Device and Biomaterial Sales.
Who are Geistlich Sons's main competitors?
Direct peers on record are Organogenesis, BioHorizons (Henry Schein), MiMedx Group, LifeNet Health, Integra LifeSciences and RTI Surgical. Broad incumbents are Medtronic, Zimmer Biomet, Dentsply Sirona and Institut Straumann (Straumann Group).
Does Geistlich Sons have an API?
No public API is recorded for Geistlich Sons.
What industry is Geistlich Sons in?
Geistlich Sons's product category is Regenerative Medical Biomaterials. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 3842.